MARKET

VYGR

VYGR

Voyager
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.50
-0.03
-0.54%
After Hours: 5.55 +0.05 +0.91% 17:56 03/08 EST
OPEN
5.59
PREV CLOSE
5.53
HIGH
5.73
LOW
5.40
VOLUME
519.68K
TURNOVER
--
52 WEEK HIGH
14.62
52 WEEK LOW
5.18
MARKET CAP
207.10M
P/E (TTM)
5.76
1D
5D
1M
3M
1Y
5Y
Coinbase IPO: Here's What All Investors Should Know Right Now
Mar 08, 2021 (Baystreet.ca via COMTEX) -- Cryptocurrencies and crypto-related companies, such as Voyager Digital Ltd. (CSE:VYGR)(OTC:VYGVF), Mogo Inc....
Baystreet.ca · 18h ago
EQUITY LOSS ALERT: Rosen, Global Investor Counsel, Encourages Voyager Therapeutics, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline VYGR
NEW YORK, NY / ACCESSWIRE / March 6, 2021 /WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ:VYGR) between June 1, 2017 and November 9, 2020, inclusive (the "Class Period"), o...
ACCESSWIRE · 2d ago
The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4)
Benzinga · 3d ago
The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 3)
Benzinga · 4d ago
VYGR Breaking Notice: Rosen, Top Ranked Investor Counsel, Encourages Voyager Therapeutics, Inc. Investors to Secure Counsel Before Important March 24 Deadline - VYGR
New York, New York--(Newsfile Corp. - March 3, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 and November 9, 2020, inclusive (the "Clas...
Newsfile · 5d ago
Voyager Digital Reports Fiscal 2021 Second Quarter Results and Provides Business Update
CSE: VYGR OTCQB: VYGVF Borse Frankfurt: UCD2
PR Newswire · 03/01 13:30
Robert W. Baird Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)
SmarterAnalyst · 03/01 09:04
Things Look Grim For Voyager Therapeutics, Inc. (NASDAQ:VYGR) After Today's Downgrade
One thing we could say about the analysts on Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) - they aren't optimistic...
Simply Wall St. · 02/28 07:41
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VYGR. Analyze the recent business situations of Voyager through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VYGR stock price target is 10.25 with a high estimate of 20.00 and a low estimate of 5.50.
EPS
Institutional Holdings
Institutions: 204
Institutional Holdings: 31.83M
% Owned: 84.53%
Shares Outstanding: 37.65M
TypeInstitutionsShares
Increased
32
2.43M
New
28
-1.03M
Decreased
34
1.82M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.02%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
President/Chief Executive Officer/Director
G. Andre Turenne
Chief Financial Officer
Allison Dorval
Chief Human Resource Officer
Michelle Smith
Senior Vice President/General Counsel
Robert Hesslein
Senior Vice President
Kelly Bales
Independent Director
James Geraghty
Other
Omar Khwaja
Director
Nancy Vitale
Independent Director
james Geraghty
Independent Director
Steven Hyman
No Data
  • All
  • Financials
  • Insiders
More
About VYGR
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington's disease; Friedreich's ataxia; frontotemporal dementia/Alzheimer's disease, and severe chronic pain. The Company's clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson's disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.

Webull offers kinds of Voyager Therapeutics Inc stock information, including NASDAQ:VYGR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VYGR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VYGR stock methods without spending real money on the virtual paper trading platform.